Peptide library / Digestive & weight / Eloralintide
Eloralintide
An investigational amylin receptor agonist from Eli Lilly in development for obesity.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Weight loss in obesitySmall human studies
How it is thought to work
Eloralintide activates amylin receptors to promote fullness and slow gastric emptying, and may be combined with incretin drugs.
What the evidence shows
A phase 2 study reported weight loss approaching 20 percent at 48 weeks in the top dose group. Phase 3 plans have been announced.
Safety and unknowns
Nausea and vomiting were the main effects. Longer-term data are lacking.
Regulatory status
Not approved. Development has moved toward phase 3.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Exenatide
FDA-approvedThe first GLP-1 receptor agonist, derived from a hormone found in Gila monster saliva.
Fragment 176-191
Wellness and performanceA piece of growth hormone sold for fat loss, closely related to AOD-9604.
Efpeglenatide
In clinical trialsA long-acting GLP-1 receptor agonist that showed heart and kidney benefit in a large trial.
General information, not medical advice. Do not buy or inject unregulated peptides.